HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
Key Details
- 1AI-CVD is cleared via FDA 510(k) by HeartLung Corporation.
- 2The platform analyzes CT images of the chest and abdomen to screen for various diseases.
- 3No additional CT sequences, radiation, or contrast are needed to use the tool.
- 4Automatically quantifies clinical measurements for cardiovascular and non-cardiovascular conditions.
- 5Diseases targeted include coronary artery disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.
Why It Matters
The clearance marks a significant step for opportunistic AI in radiology, enabling wider disease detection from standard CT scans without extra imaging, doses, or disruptions. This has the potential to improve early diagnosis and make radiology workflows more efficient.
Source
Radiology Business
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
Study Finds Disparities in Access to Stroke Imaging AI Tools
Research shows access to AI stroke detection tools is concentrated in resource-rich hospitals despite Medicare incentives.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.